J.P. Donnelly

TL;DR: The data suggest that the inflammatory response after conditioning for a HSCT is the result of the chemotherapy-induced mucositis and independent of neutropenia, suggesting a causative role for mucposis in the occurrence of bacteraemia.

TL;DR: This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe, and indicates that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azoles, and the presence of potentially antIFungal drug-resistant Candida species.

TL;DR: The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.

TL;DR: A significant increase of interleukin-8, LBP and CRP mirroring the pattern of mucosal barrier injury as measured by gut integrity and daily mucositis score and serum citrulline concentrations of 32 haematopoietic stem cell transplant recipients following intensive myeloablative therapy suggests that the degree of mucosa barrier injury rather than bacteraemia due to OVS determines the intensity of the inflammatory response.

TL;DR: The EBV protocol proved feasible and resulted in faster initiation of pre-emptive therapy, the diagnosis in an earlier stage of EBV disease, and decreased EBV-related mortality.